Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study
Abstract Background Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for patients with colorectal peritoneal carcinomatosis. However, standardizat...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12957-019-1618-4 |
| _version_ | 1818495747901882368 |
|---|---|
| author | Atuhani Burnett Marie-Eve Aubé Lecompte Nora Trabulsi Pierre Dubé Mai-Kim Gervais Bertrand Trilling Alexis-Simon Cloutier Lucas Sideris |
| author_facet | Atuhani Burnett Marie-Eve Aubé Lecompte Nora Trabulsi Pierre Dubé Mai-Kim Gervais Bertrand Trilling Alexis-Simon Cloutier Lucas Sideris |
| author_sort | Atuhani Burnett |
| collection | DOAJ |
| description | Abstract Background Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for patients with colorectal peritoneal carcinomatosis. However, standardization of HIPEC protocols, including which chemotherapeutic agent to use, is lacking in the literature. Therefore, we sought to report survival outcomes from colorectal cancer patients undergoing CRS/oxaliplatin-based HIPEC at our institution over the last 10 years. Methods Colorectal PC patients treated with CRS/oxaliplatin-based HIPEC 2004–2015 were included. Demographic, clinical, and oncologic data were abstracted from the medical record. Overall (OS) and disease-free survival (DFS) were calculated using Kaplan–Meier analysis. Univariate/multivariate Cox regression analysis was done. Results Laparotomy was performed in 113 patients for colorectal PC; 91 completed a curative intent CRS/HIPEC. At 3 and 5 years, OS for the CRS/HIPEC cohort was 75% and 55%, and DFS was 50% and 25%, respectively. On multivariate analysis, incremental increases in peritoneal carcinomatosis index (PCI) were associated with worse OS (p = 0.0001) and DFS (p = 0.0001). Grade III/IV complications were also associated with worse OS. Conclusions A standardized regimen of CRS and oxaliplatin-based HIPEC for colorectal PC is effective with favorable OS and DFS and acceptable complication rates. |
| first_indexed | 2024-12-10T18:24:50Z |
| format | Article |
| id | doaj.art-7ddc21e047eb4ab88f519f56dd56e028 |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-12-10T18:24:50Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-7ddc21e047eb4ab88f519f56dd56e0282022-12-22T01:38:06ZengBMCWorld Journal of Surgical Oncology1477-78192019-05-0117111010.1186/s12957-019-1618-4Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort studyAtuhani Burnett0Marie-Eve Aubé Lecompte1Nora Trabulsi2Pierre Dubé3Mai-Kim Gervais4Bertrand Trilling5Alexis-Simon Cloutier6Lucas Sideris7Banner MD Anderson Cancer CenterCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalCentre de Recherche, Hôpital Maisonneuve-Rosemont, Université de MontréalAbstract Background Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for patients with colorectal peritoneal carcinomatosis. However, standardization of HIPEC protocols, including which chemotherapeutic agent to use, is lacking in the literature. Therefore, we sought to report survival outcomes from colorectal cancer patients undergoing CRS/oxaliplatin-based HIPEC at our institution over the last 10 years. Methods Colorectal PC patients treated with CRS/oxaliplatin-based HIPEC 2004–2015 were included. Demographic, clinical, and oncologic data were abstracted from the medical record. Overall (OS) and disease-free survival (DFS) were calculated using Kaplan–Meier analysis. Univariate/multivariate Cox regression analysis was done. Results Laparotomy was performed in 113 patients for colorectal PC; 91 completed a curative intent CRS/HIPEC. At 3 and 5 years, OS for the CRS/HIPEC cohort was 75% and 55%, and DFS was 50% and 25%, respectively. On multivariate analysis, incremental increases in peritoneal carcinomatosis index (PCI) were associated with worse OS (p = 0.0001) and DFS (p = 0.0001). Grade III/IV complications were also associated with worse OS. Conclusions A standardized regimen of CRS and oxaliplatin-based HIPEC for colorectal PC is effective with favorable OS and DFS and acceptable complication rates.http://link.springer.com/article/10.1186/s12957-019-1618-4Colorectal cancerHIPECOxaliplatinPeritoneal carcinomatosis |
| spellingShingle | Atuhani Burnett Marie-Eve Aubé Lecompte Nora Trabulsi Pierre Dubé Mai-Kim Gervais Bertrand Trilling Alexis-Simon Cloutier Lucas Sideris Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study World Journal of Surgical Oncology Colorectal cancer HIPEC Oxaliplatin Peritoneal carcinomatosis |
| title | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| title_full | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| title_fullStr | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| title_full_unstemmed | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| title_short | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study |
| title_sort | peritoneal carcinomatosis index predicts survival in colorectal patients undergoing hipec using oxaliplatin a retrospective single arm cohort study |
| topic | Colorectal cancer HIPEC Oxaliplatin Peritoneal carcinomatosis |
| url | http://link.springer.com/article/10.1186/s12957-019-1618-4 |
| work_keys_str_mv | AT atuhaniburnett peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT marieeveaubelecompte peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT noratrabulsi peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT pierredube peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT maikimgervais peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT bertrandtrilling peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT alexissimoncloutier peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy AT lucassideris peritonealcarcinomatosisindexpredictssurvivalincolorectalpatientsundergoinghipecusingoxaliplatinaretrospectivesinglearmcohortstudy |